Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9367097 | 0.84 | — | — | |
| SCHEMBL38660196 | 0.82 | LMNA (0.32) | — | |
| SCHEMBL10706424 | 0.82 | CYP1A2 (0.33) | CYP1A2CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8568766 | 0.81 | ALDH1A1 (0.30) | — | |
| SCHEMBL27671098 | 0.80 | — | — | |
| SCHEMBL27993329 | 0.78 | MGAM (0.36) | CYP1A2 | |
| SCHEMBL31512459 | 0.77 | — | — | |
| SCHEMBL28615436 | 0.77 | — | — | |
| SCHEMBL6471572 | 0.76 | HSD11B1 (0.31) | — | |
| SCHEMBL9815333 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61115090-A | — | — | None | — | — | JP | disclosed |
| CN-110872235-A | Application of novel methyl carbonate methylation catalyst in preparation of α -methylphenylacetic acid | 江苏瑞科医药科技有限公司 | 2020-03-10 | — | — | CN | disclosed |
| CN-110872237-A | Application of novel methyl carbonate methylation catalyst in preparation of α -methylphenylacetic acid | 江苏瑞科医药科技有限公司 | 2020-03-10 | — | — | CN | disclosed |
| EP-1581476-B1 | AMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-16 | — | — | EP | disclosed |
| EP-2995615-A1 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR PHARMACEUTICAL USE | AstraZeneca AB (SE) | 2016-03-16 | — | — | EP | disclosed |
| CN-104276952-B | The preparation method of bilastine key intermediate | NANJING HUAWE MEDICAL SCIENCE & TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2016-03-02 | — | — | CN | disclosed |
| EP-2272825-B1 | Protected amino hydroxy adamantane carboxylic acid and process for its preparation | ASTRAZENECA AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| CN-104276952-A | Preparation method of bilastine key intermediate | NANJING HUAWE MEDICAL TECHNOLOGY DEV CO LTD | 2015-01-14 | — | — | CN | disclosed |
| EP-1559710-B1 | Dipeptidyl peptidase IV inhibitors based on cyclopropyl-fused pyrrolidine, process for their preparation and their use | BRISTOL MYERS SQUIBB CO (US) | 2014-02-26 | — | — | EP | disclosed |
| US-RE44186-E1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2004056744-A1 | ADAMANTYL ACETAMIDES AS HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056745-A2 | ADAMANTYL ACETAMIDES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-07-08 | — | — | WO | disclosed |
| CN-1427826-A | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV, methods for their preparation and uses thereof | BRISTOL MYERS SQUIBB CO (US) | 2003-07-02 | — | — | CN | disclosed |
| EP-1261586-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL PEPTIDASE IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | Bristol-Myers Squibb Company (US) | 2002-12-04 | — | — | EP | disclosed |
| US-6395767-B2 | ANTIDIABETIC AGENTS; SAXAGLIPTIN | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-28 | — | — | US | disclosed |
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | US | disclosed |
| WO-2001068603-A2 | CYCLOPROPYL-FUSED PYRROLIDINE-BASED INHIBITORS OF DIPEPTIDYL IV, PROCESSES FOR THEIR PREPARATION, AND THEIR USE | BRISTOL-MYERS SQUIBB CO. (US) | 2001-09-20 | — | — | WO | disclosed |
| EP-0346791-B1 | 1,2-diarylethylamines for treatment of neurotoxic injury | SEARLE & CO (US) | 1994-04-06 | — | — | EP | disclosed |
| EP-0346791-A1 | 1,2-diarylethylamines for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1989-12-20 | — | — | EP | disclosed |
| JP-S61115090-A | TRICYCLOHEXYLTIN CARBOXYLIC ACID ESTER, PRODUCTION THEREOF, AND ACARICIDE COMPRISING SAME AS ACTIVE INGREDIENT | KYODO YAKUHIN KK | 1986-06-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019411-A1 | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method | DPP4, DPP3, DPP7 | CYP1A2 768/4885CYP2D6 325/4885CYP2C9 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.